Gastrointestinal, or GI, issues are common in the United States, with as many as 70 million people diagnosed with some form of digestive disease, as found by the National Institute of Diabetes and Digestive Kidney Diseases. Since each person’s case varies, patients’ conditions can require complex care to rectify the disease, according to Oshi Health, a New York-based care company specializing in GI healthcare.
Looking to offer a personalized care solution to individuals with GI conditions, Oshi secured a Series B round of funding to expand its virtual care platform. Koch Disruptive Technologies led the $30 million investment that will help Oshi further its current growth momentum.
Oshi’s healthcare model hinges on its mobile app where users can meet virtually with GI care providers about a range of conditions, such as gastroesophageal reflux disease, or GERD, and irritable bowel syndrome, or IBS. Oshi’s network of providers consists of board-certified gastroenterologists, registered dietitians, GI-specialized mental health clinicians and nurse practitioners, according to a company release.
The platform works to help intercept condition escalation due to unmanaged symptoms through diagnosing, prescribing, treating and coordinating care. Through iterative treatment and response, Oshi’s solution aims to help providers pinpoint the root causes of members’ chronic digestive symptoms and help members understand their dietary and psychological triggers.
Currently, Oshi’s platform is available to more than 20 million people as an in-network virtual gastroenterology clinic for national and regional insurers and their employer customers, according to Oshi. The company also recently launched a collaboration with care company Aetna to provide virtual digestive disorder care to certain members.
“We’ve paved the way for broad access to proven treatments that our traditional healthcare system is not structured or incentivized to provide while building value for patients, employers, health plans and provider groups,” Sam Holliday, CEO of Oshi Health, said in a statement.
The company will put its Series B funding toward scaling its clinical team nationwide as well as working with health plans, employers, channel partners and provider groups to further the reach of its offering.
“Our investors are collectively funding the change-makers in the most crucial categories of healthcare,” Holliday said. “They see the transformation opportunity and urgency in digestive care as clearly as we do, and we’re proud to have them back our mission to free millions of Americans from their struggle with digestive symptoms and conditions.”
